These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 20703506)

  • 1. Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort.
    Hiemenz JW; Raad II; Maertens JA; Hachem RY; Saah AJ; Sable CA; Chodakewitz JA; Severino ME; Saddier P; Berman RS; Ryan DM; Dinubile MJ; Patterson TF; Denning DW; Walsh TJ
    Eur J Clin Microbiol Infect Dis; 2010 Nov; 29(11):1387-94. PubMed ID: 20703506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study.
    Kartsonis NA; Saah AJ; Joy Lipka C; Taylor AF; Sable CA
    J Infect; 2005 Apr; 50(3):196-205. PubMed ID: 15780413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin.
    Raad II; Hanna HA; Boktour M; Jiang Y; Torres HA; Afif C; Kontoyiannis DP; Hachem RY
    Leukemia; 2008 Mar; 22(3):496-503. PubMed ID: 18094720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis.
    Keating G; Figgitt D
    Drugs; 2003; 63(20):2235-63. PubMed ID: 14498760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evidence for caspofungin monotherapy in the first-line and salvage therapy of invasive Aspergillus infections.
    Heinz WJ; Buchheidt D; Ullmann AJ
    Mycoses; 2016 Aug; 59(8):480-93. PubMed ID: 27324802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy.
    Maertens J; Raad I; Petrikkos G; Boogaerts M; Selleslag D; Petersen FB; Sable CA; Kartsonis NA; Ngai A; Taylor A; Patterson TF; Denning DW; Walsh TJ;
    Clin Infect Dis; 2004 Dec; 39(11):1563-71. PubMed ID: 15578352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies.
    Raad II; Zakhem AE; Helou GE; Jiang Y; Kontoyiannis DP; Hachem R
    Int J Antimicrob Agents; 2015 Mar; 45(3):283-8. PubMed ID: 25455847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caspofungin as first-line therapy for the treatment of invasive aspergillosis after thoracic organ transplantation.
    Groetzner J; Kaczmarek I; Wittwer T; Strauch J; Meiser B; Wahlers T; Daebritz S; Reichart B
    J Heart Lung Transplant; 2008 Jan; 27(1):1-6. PubMed ID: 18187079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High rate of breakthrough invasive aspergillosis among patients receiving caspofungin for persistent fever and neutropenia.
    Lafaurie M; Lapalu J; Raffoux E; Breton B; Lacroix C; SociƩ G; Porcher R; Ribaud P; Touratier S; Molina JM
    Clin Microbiol Infect; 2010 Aug; 16(8):1191-6. PubMed ID: 19735276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disseminated Aspergillus terreus infection arising from cutaneous inoculation treated with caspofungin.
    Cooke FJ; Terpos E; Boyle J; Rahemtulla A; Rogers TR
    Clin Microbiol Infect; 2003 Dec; 9(12):1238-41. PubMed ID: 14686991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis.
    Maertens J; Glasmacher A; Herbrecht R; Thiebaut A; Cordonnier C; Segal BH; Killar J; Taylor A; Kartsonis N; Patterson TF; Aoun M; Caillot D; Sable C;
    Cancer; 2006 Dec; 107(12):2888-97. PubMed ID: 17103444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
    Moen MD; Lyseng-Williamson KA; Scott LJ
    Drugs; 2009; 69(3):361-92. PubMed ID: 19275278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Caspofungin after solid organ transplantation in Germany: observational study on treatment of invasive fungal infections].
    Lichtenstern C; Pratschke J; Schulz U; Schmoeckel M; Knitsch W; Kaskel P; Krobot KJ; Weigand MA; Winkler M
    Anaesthesist; 2010 Dec; 59(12):1083-90. PubMed ID: 21069271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin.
    Aliff TB; Maslak PG; Jurcic JG; Heaney ML; Cathcart KN; Sepkowitz KA; Weiss MA
    Cancer; 2003 Feb; 97(4):1025-32. PubMed ID: 12569602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Caspofungin use in daily clinical practice for treatment of invasive aspergillosis: results of a prospective observational registry.
    Maertens J; Egerer G; Shin WS; Reichert D; Stek M; Chandwani S; Shivaprakash M; Viscoli C;
    BMC Infect Dis; 2010 Jun; 10():182. PubMed ID: 20569436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis.
    van Vianen W; de Marie S; ten Kate MT; Mathot RA; Bakker-Woudenberg IA
    J Antimicrob Chemother; 2006 Apr; 57(4):732-40. PubMed ID: 16464895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The first echinocandin: caspofungin.
    Cornely OA; Schmitz K; Aisenbrey S
    Mycoses; 2002; 45 Suppl 3():56-60. PubMed ID: 12690973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies.
    Kontoyiannis DP; Hachem R; Lewis RE; Rivero GA; Torres HA; Thornby J; Champlin R; Kantarjian H; Bodey GP; Raad II
    Cancer; 2003 Jul; 98(2):292-9. PubMed ID: 12872348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients.
    Betts R; Glasmacher A; Maertens J; Maschmeyer G; Vazquez JA; Teppler H; Taylor A; Lupinacci R; Sable C; Kartsonis N
    Cancer; 2006 Jan; 106(2):466-73. PubMed ID: 16353208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B.
    Offner F; Krcmery V; Boogaerts M; Doyen C; Engelhard D; Ribaud P; Cordonnier C; de Pauw B; Durrant S; Marie JP; Moreau P; Guiot H; Samonis G; Sylvester R; Herbrecht R;
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4808-12. PubMed ID: 15561860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.